Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
09 May 2014 07:00 AM
RNS
Avacta Announce Collaboration with UbiQ Bio BV
07 May 2014 07:00 AM
RNS
Conditional Placing
23 Apr 2014 07:00 AM
RNS
Interim Results
14 Apr 2014 07:00 AM
RNS
Avacta Launch Pancreatitis Test for Dogs
20 Mar 2014 07:00 AM
RNS
Affimers : Technical and Commercial Update
11 Mar 2014 07:00 AM
RNS
Notice of Interim Results
24 Feb 2014 07:00 AM
RNS
Directors Dealings
05 Feb 2014 07:00 AM
RNS
New Board Appointment
04 Feb 2014 09:29 AM
RNS
Holding(s) in Company
03 Feb 2014 07:00 AM
RNS
Avacta Initiates Collaboration with University
28 Jan 2014 07:00 AM
RNS
Avacta Life Sciences Launches Affimers Web Site
24 Jan 2014 02:57 PM
RNS
Result of AGM
24 Jan 2014 07:00 AM
RNS
AGM Statement
20 Jan 2014 07:00 AM
RNS
Issue of Equity
13 Jan 2014 07:00 AM
RNS
Investor teach-in
23 Dec 2013 02:59 PM
RNS
Notice of AGM and Report and Accounts
23 Dec 2013 07:00 AM
RNS
Board Appointment
27 Nov 2013 10:01 AM
RNS
New Canine Lymphoma Blood Test Launched
01 Nov 2013 07:00 AM
RNS
Issue of Equity
24 Oct 2013 07:00 AM
RNS
Preliminary Results
17 Oct 2013 07:00 AM
RNS
First therapeutic licensing agreement for Affimers
26 Sep 2013 07:00 AM
RNS
Launch of Sensipod - First Point of Care Test
18 Sep 2013 07:00 AM
RNS
Issue of Equity and Notice of Preliminary Results
16 Sep 2013 07:00 AM
RNS
New Head of R&D Joins Avacta
02 Sep 2013 05:47 PM
RNS
TR-1 Notification of Major Interest in Shares
29 Aug 2013 07:00 AM
RNS
Pre-close trading update
28 Aug 2013 07:00 AM
RNS
Issue of Equity
09 Aug 2013 08:35 AM
RNS
TR-1: Notification of Major Interest in Shares
07 Aug 2013 05:51 PM
RNS
TR-1: Notification of Major Interest in Shares
07 Aug 2013 04:31 PM
RNS
TR-1: Notification of Major Interest in Shares
07 Aug 2013 04:30 PM
RNS
TR-1: Notification of Major Interest in Shares
07 Aug 2013 04:00 PM
RNS
TR-1: Notification of Major Interest in Shares
05 Aug 2013 11:00 AM
RNS
Result of General Meeting
05 Aug 2013 07:00 AM
RNS
Appointment of a Non-Executive Director
25 Jul 2013 07:00 AM
RNS
Expansion of Collaboration with ForteBio
18 Jul 2013 07:00 AM
RNS
Conditional Placing to Raise ?4.7 Million
23 May 2013 08:40 AM
RNS
Holding(s) in Company
30 Apr 2013 07:00 AM
RNS
Interim Results
23 Apr 2013 07:01 AM
RNS
Notice of Interim Results
23 Apr 2013 07:00 AM
RNS
Appointment of Nominated Advisor and Broker
27 Feb 2013 07:00 AM
RNS
Interest in Affimer Technology
27 Feb 2013 07:00 AM
RNS
Business Update
18 Feb 2013 05:08 PM
RNS
Additional Listing
25 Jan 2013 02:34 PM
RNS
Result of AGM
21 Jan 2013 01:20 PM
RNS
Holding(s) in Company
07 Jan 2013 03:47 PM
RNS
Holding(s) in Company
23 Oct 2012 07:00 AM
RNS
Preliminary Results
24 Sep 2012 07:00 AM
RNS
Avacta and Pall extend Optim distribution to India
13 Sep 2012 10:24 AM
RNS
Notice of Preliminary Results
24 Aug 2012 07:00 AM
RNS
Pre-close trading update

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100

Latest directors dealings